Advice
In the absence of a submission from the holder of the marketing authorisation:
lumasiran (Oxlumo®) is not recommended for use within NHSScotland.
Indication under review: Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice233KB (PDF)
Medicine details
- Medicine name:
- lumasiran (Oxlumo)
- SMC ID:
- SMC2639
- Indication:
For treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
- Pharmaceutical company
- Alnylam Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 December 2023